Ipsen Acquires Kartos Therapeutics for Up To $1.75 Billion

French pharmaceutical giant Ipsen is making a significant strategic move, agreeing to acquire Kartos Therapeutics in a deal valued at up to $1.75 billion. This acquisition is designed to bolster Ipsen's hemato-oncology portfolio with Kartos' promising late-stage asset, navtemadlin, currently in Phase III development for myelofibrosis.

The transaction structure includes an upfront payment of $450 million, with the potential for an additional $1.3 billion in milestone payments contingent upon regulatory approvals and sales performance. This forward-looking financial arrangement underscores Ipsen's confidence in navtemadlin's therapeutic potential. The deal is anticipated to close by the end of the third quarter of 2026, pending standard regulatory reviews, including the Hart-Scott-Rodino Act waiting period.

Navtemadlin, an investigational oral MDM2 inhibitor, targets a critical pathway in myelofibrosis, a rare and debilitating blood cancer. By aiming to restore the natural tumor-suppressing function of p53, the drug shows particular promise as an add-on therapy for patients with intermediate- and high-risk TP53 wild-type myelofibrosis who exhibit a suboptimal response to the current standard of care, ruxolitinib. This addresses a clear unmet need, as a substantial portion of patients do not achieve optimal outcomes with existing treatments, facing poor prognoses after discontinuation.

The Phase III POIESIS trial, a cornerstone of navtemadlin's development, is actively enrolling over 600 patients globally and is expected to yield top-line data in 2027. Earlier clinical studies have demonstrated navtemadlin's ability to significantly reduce spleen volume and improve symptom scores in patients with suboptimal responses to ruxolitinib. Notably, data presented at the European Hematology Association Congress in 2023 indicated that a considerable percentage of patients experienced meaningful reductions in spleen size and symptom burden, alongside encouraging signs of potential disease modification, including reductions in driver variant allele frequency and improvements in bone marrow fibrosis.

Myelofibrosis, affecting approximately 1.5 per 100,000 individuals in the U.S. and Europe, is characterized by bone marrow scarring, enlarged spleen, and severe symptoms, significantly impacting patient quality of life and carrying a risk of transformation to acute myeloid leukemia. The median age at diagnosis is around 67-69 years, highlighting the need for effective therapeutic interventions for this patient demographic.

This acquisition is projected to be accretive to Ipsen's core operating income starting in 2029, with minimal impact on its 2026 financial guidance. The deal was supported by financial advisory services from Goldman Sachs and PJT Partners for Kartos Therapeutics, with DLA Piper serving as Kartos' legal counsel. Orrick Herrington & Sutcliffe provided legal counsel to Ipsen.